½ÃÀ庸°í¼­
»óǰÄÚµå
1601217

µÅÁö ¹é½Å ½ÃÀå : ÀûÀÀÁõº°, ±â¼úº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Porcine Vaccines Market by Indication (Arthritis, Diarrhea, Porcine Circovirus Associated Disease), Technology (Conjugate Vaccines, DNA Vaccines, Inactivated Vaccines), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

µÅÁö ¹é½Å ½ÃÀåÀº 2023³â¿¡ 17¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 18¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.72%·Î ¼ºÀåÇϰí 2030³â¿¡´Â 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µÅÁö ¹é½Å ½ÃÀåÀº µÅÁö¸¦ Àü¿°º´À¸·ÎºÎÅÍ º¸È£ÇÏ°í ¼Ò±ºÀÇ °Ç°­°ú »ý»ê¼ºÀ» Çâ»ó½ÃŰ´Â ¹é½ÅÀÇ °³¹ß, »ý»ê, À¯ÅëÀ» Æ÷°ýÇϰí ÀÖ½À´Ï´Ù. »ê¾÷ÀÇ °æÁ¦Àû ¼Õ½ÇÀ» ¸·À» Çʿ伺¿¡ µû¶ó¼­ ÀÌ ¹é½ÅÀº µÅÁö »çÄÚ¹ÙÀÌ·¯½º, µÅÁö ¹ø½Ä¡¤È£Èí±â ÁõÈıº ¹ÙÀÌ·¯½º(PRRSV) µîÀÇ º´¿øÃ¼¸¦ ´ë»óÀ¸·Î ´Ù¾çÇÑ ¿¬·ÉÃþÀÇ µÅÁö¿¡ ÁÖ»ç ¶Ç´Â °æ±¸ Åõ¿©µË´Ï´Ù. ÁÖ·Î µ¿¹°º´¿ø, ³ó Àå, ¿¬±¸ ±â°üÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ¼ºÀåÀº µÅÁö°í±â ¼Òºñ·® Áõ°¡, µ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, ¹é½Å ±â¼úÀÇ Áøº¸¿¡ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ³î·ÎÁöÀÇ ÃÖ±Ù ±â¼ú Çõ½ÅÀº À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Áö¼Ó °¡´ÉÇÑ ³ó¹ýÀ» ¸ñÇ¥·Î Ãß¼¼°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ·¯ÇÑ ±âÁØ¿¡ ºÎÇÕÇÏ´Â ¹é½Å¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼º µîÀÇ Á¦¾àÀÌ ÀÖ½À´Ï´Ù.¶Ç, ¹é½ÅÀÇ º¸°üÀ̳ª À¯ÅëÀÇ ·ÎÁö½ºÆ½½º¿¡µµ °úÁ¦°¡ ÀÖ¾î, ¼¼°èÀûÀ¸·Î µÅÁö°¡ »çÀ°µÇ°í ÀÖ´Â ±âÈİ¡ ´Ù¾çÇϱ⠶§¹®¿¡ ƯÈ÷ º¹ÀâÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. »õ·Î¿î º´¿øÃ¼ÀÇ ÃâÇö°ú ÁÖ½ÄÀÇ º¯È­´Â ¹é½Å Á¦ÇüÀÇ Áö¼ÓÀûÀÎ ¿¬±¸¿Í ÀûÀÀÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. °¡´ÉÇÑ ´Ù±â´É ¹é½ÅÀÇ °³¹ßÀÔ´Ï´Ù. ÄíÆ¾ Àü´ÞÀ» À§ÇÑ ³ª³ë±â¼ú°ú º´¿øÃ¼ ³»¼ºÀÌ ÀÖ´Â À¯ÀüÀÚ ÀçÁ¶ÇÕ µÅÁöÀÇ Á¶»çµµ ÀáÀçÀûÀÎ °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 17¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 18¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 27¾ï ´Þ·¯
CAGR(%) 6.72%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â µÅÁö ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

µÅÁö ¹é½Å ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°è µÅÁö Áúº´ÀÇ À¯Çà Áõ°¡
    • °íǰÁú µÅÁö°í±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • µ¿¹°ÀÇ °Ç°­À» Áö¿øÇÏ´Â Á¤ºÎÀÇ ´ëó
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • µÅÁö ¹é½Å °³¹ß ºñ¿ëÀÇ »ó½Â°ú º¹ÀâÇÑ º¸°ü ¹®Á¦
  • ½ÃÀå ±âȸ
    • µÅÁö ¹é½ÅÀÇ ±â¼úÀû Áøº¸
    • ½Å±Ô µÅÁö ¹é½Å Á¦Á¶¸¦ À§ÇÑ À¯¸®ÇÑ ÅõÀÚ È¯°æ
  • ½ÃÀåÀÇ °úÁ¦
    • µÅÁö ¹é½Å°ú °ü·ÃµÈ ºÎÀÛ¿ë°ú ÇÔ²² Á¦ÇÑµÈ ÀÌ¿ë °¡´É¼º°ú ÀÎÁöµµ

Porter's Five Forces: µÅÁö ¹é½Å ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â µÅÁö ¹é½Å ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. Äí´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇÇÇÒ ¼ö ÀÖÀ¸¸ç ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : µÅÁö ¹é½Å ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº µÅÁö ¹é½Å ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À» ¿¹ÃøÇÏ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® µÅÁö ¹é½Å ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

µÅÁö ¹é½Å ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹à°Ô À̸¦ ÅëÇØ ½ÃÀåÀÇ ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º µÅÁö ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â µÅÁö ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è µÅÁö Áúº´ÀÇ ¸¸¿¬ÀÌ Áõ°¡
      • °íǰÁú µÅÁö°í±â ¼ö¿ä Áõ°¡
      • µ¿¹°ÀÇ °Ç°­À» Áö¿øÇÏ´Â Á¤ºÎÀÇ ´ëó
    • ¾ïÁ¦¿äÀÎ
      • µÅÁö ¹é½Å °³¹ßÀÇ °íºñ¿ë°ú º¹ÀâÇÑ º¸°ü ¹®Á¦
    • ±âȸ
      • µÅÁö ¹é½ÅÀÇ ±â¼úÀû Áøº¸
      • ¼Ò¼³ÀÇ Á¦ÀÛ¿¡ À¯¸®ÇÑ ÅõÀÚ Á¤¼¼ µÅÁö ¹é½Å
    • °úÁ¦
      • µÅÁö ¹é½Å°ú °ü·ÃµÈ ºÎÀÛ¿ë°ú ÇÔ²² ÀÔ¼ö¼º ¹× ÀÎÁöµµ Á¦ÇÑ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • ±â¼ú: À¯ÀüÀÚ °øÇаú ºÐÀÚ »ý¹°ÇÐ ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ÀçÁ¶ÇÕ ¹é½ÅÀÇ Çõ½ÅÀÌ ÁøÇàµÈ´Ù.
    • ÃÖÁ¾ »ç¿ëÀÚ : µÅÁö »ý»ê ³óÀå¿¡¼­ Áý´Ü ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÇ Çʿ伺 Áõ°¡
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »çȸ
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå µÅÁö ¹é½Å ½ÃÀå : ÀûÀÀÁõº°

  • °üÀý¿°
  • ¼³»ç
  • µÅÁö »çÄÚ¹ÙÀÌ·¯½º °ü·Ã Áúȯ
  • µÅÁö ¹ø½Ä È£Èí±â ÁõÈıº
  • µÅÁöµ¶°¨

Á¦7Àå µÅÁö ¹é½Å ½ÃÀå : ±â¼úº°

  • °áÇÕ ¹é½Å
  • DNA ¹é½Å
  • ºÒȰȭ ¹é½Å
  • »ý¾àµ¶È­ ¹é½Å
  • ÀçÁ¶ÇÕ ¹é½Å
  • Åå¼ÒÀÌµå ¹é½Å

Á¦8Àå µÅÁö ¹é½Å ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¾çµ·³óÀå
  • ¼öÀÇ Å¬¸®´Ð/º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ µÅÁö ¹é½Å ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µÅÁö ¹é½Å ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µÅÁö ¹é½Å ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Á¶¿¡Æ¼½º, ¼­Äڸƽº¸¦ ¿µ±¹¿¡¼­ ¹ß¸Å
    • ¸ÓÅ© µ¿¹° °Ç°­, 3-in-1 µÅÁö ¹é½ÅÀ» ¹ß¸Å
    • ¿¤¶õÄÚ´Â ¾ÛƼ¹ÀÀÇ PRRS ºÒȰȭ ÀÚ°¡ ¹é½ÅÀÇ ¹Ì±¹ µ¶Á¡ À¯Åë¾÷üÀÔ´Ï´Ù.

±â¾÷ ¸ñ·Ï

  • Bayer AG
  • Endovac Animal Health
  • Merck & Co., Inc.
  • FATRO SpA
  • Malaysian Vaccines & Pharmaceuticals Sdn Bhd.
  • Yenher Agro-Products Sdn. Bhd.
  • Boehringer Ingelheim International GmbH
  • Biogenesis Bago SA
  • Formosa Biomedical Inc.
  • Indian Immunologicals Ltd.
  • Kyoto Biken Laboratories, Inc.
  • PBS Animal Health
  • Bimeda Holdings PLC
  • HIPRA, SA
  • Zoetis Inc.
  • Aptimmune Biologics, Inc.
  • AVAC Vietnam Joint Stock Company
  • Eli Lilly and Company
  • Phibro Animal Health Corporation
  • Arko Laboratories
  • Genvax Technologies, Inc.
  • Nisseiken Co., Ltd.
  • Medgene Labs
  • Virbac SA
  • Ceva Sante Animale
  • KM Biologics Co., Ltd.
KSA 24.12.06

The Porcine Vaccines Market was valued at USD 1.71 billion in 2023, expected to reach USD 1.82 billion in 2024, and is projected to grow at a CAGR of 6.72%, to USD 2.70 billion by 2030.

The porcine vaccines market encompasses the development, production, and distribution of vaccines used to protect pigs from infectious diseases, thereby enhancing herd health and productivity. The necessity for such vaccines is driven by the need to prevent economic losses in the swine industry due to disease outbreaks. These vaccines are applied via injection or oral administration to pigs of various age groups, targeting pathogens like Porcine Circovirus, Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), and others. End-use scope primarily includes veterinary clinics, farms, and research institutions. Market growth is significantly influenced by rising pork consumption, increased awareness of animal health, and advancements in vaccine technology. Recent innovations in genetic and biotechnology such as recombinant vaccines and DNA vaccines offer lucrative opportunities. Companies can capitalize on these by investing in R&D for more effective and easy-to-administer vaccines. Additionally, the growing trend towards organic and sustainable farming practices highlights the demand for vaccines that comply with such standards. However, limitations include stringent regulatory frameworks that slow down the approval process, high development costs, and limited awareness and accessibility in developing regions. Challenges also arise from vaccine storage and distribution logistics, which can be particularly complex given the diverse climates in which swine are raised globally. Furthermore, the emergence of new pathogens and changing strains emphasize the need for continuous research and adaptation in vaccine formulation. Innovation can focus on enhancing the efficacy and duration of immunity of vaccines, as well as developing multifunctional vaccines that can combat multiple diseases in a single dose. Research into nanotechnology for vaccine delivery and pathogen-resistant genetically modified pigs also presents potential avenues. The market is dynamic with intense competition, witnessing a steady shift towards biologic solutions-a trend that market players must monitor to harness upcoming opportunities effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.71 billion
Estimated Year [2024] USD 1.82 billion
Forecast Year [2030] USD 2.70 billion
CAGR (%) 6.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Porcine Vaccines Market

The Porcine Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in Prevalence of Swine Diseases Worldwide
    • Increasing Demand for High-Quality Pork Meat
    • Government Initiatives to Support Animal Health
  • Market Restraints
    • High Cost of Porcine Vaccine Development and Complex Storage Issues
  • Market Opportunities
    • Technological Advancements in Porcine Vaccine
    • Favorable Investment Landscape For Production of Novel Porcine Vaccines
  • Market Challenges
    • Limited Availability and Awareness Along with Side Effects Associated with Porcine Vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Porcine Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Porcine Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Porcine Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Porcine Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Porcine Vaccines Market

A detailed market share analysis in the Porcine Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Porcine Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Porcine Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Porcine Vaccines Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Endovac Animal Health, Merck & Co., Inc., FATRO S.p.A., Malaysian Vaccines & Pharmaceuticals Sdn Bhd., Yenher Agro-Products Sdn. Bhd., Boehringer Ingelheim International GmbH, Biogenesis Bago S.A., Formosa Biomedical Inc., Indian Immunologicals Ltd., Kyoto Biken Laboratories, Inc., PBS Animal Health, Bimeda Holdings PLC, HIPRA, S.A., Zoetis Inc., Aptimmune Biologics, Inc., AVAC Vietnam Joint Stock Company, Eli Lilly and Company, Phibro Animal Health Corporation, Arko Laboratories, Genvax Technologies, Inc., Nisseiken Co., Ltd., Medgene Labs, Virbac SA, Ceva Sante Animale, and KM Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Porcine Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Arthritis, Diarrhea, Porcine Circovirus Associated Disease, Porcine Reproductive & Respiratory Syndrome, and Swine Influenza.
  • Based on Technology, market is studied across Conjugate Vaccines, DNA Vaccines, Inactivated Vaccines, Live attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines.
  • Based on End User, market is studied across Hog/Pig Production Farm and Veterinary Clinics/Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in Prevalence of Swine Diseases Worldwide
      • 5.1.1.2. Increasing Demand for High-Quality Pork Meat
      • 5.1.1.3. Government Initiatives to Support Animal Health
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost of Porcine Vaccine Development and Complex Storage Issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological Advancements in Porcine Vaccine
      • 5.1.3.2. Favorable Investment Landscape For Production of Novel Porcine Vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Availability and Awareness Along with Side Effects Associated with Porcine Vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Growing innovations in recombinant vaccines due to advancements in genetic engineering and molecular biology technologies
    • 5.2.2. End User: Growing need for mass vaccination programs in the hog/pig production farm
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Porcine Vaccines Market, by Indication

  • 6.1. Introduction
  • 6.2. Arthritis
  • 6.3. Diarrhea
  • 6.4. Porcine Circovirus Associated Disease
  • 6.5. Porcine Reproductive & Respiratory Syndrome
  • 6.6. Swine Influenza

7. Porcine Vaccines Market, by Technology

  • 7.1. Introduction
  • 7.2. Conjugate Vaccines
  • 7.3. DNA Vaccines
  • 7.4. Inactivated Vaccines
  • 7.5. Live attenuated Vaccines
  • 7.6. Recombinant Vaccines
  • 7.7. Toxoid Vaccines

8. Porcine Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Hog/Pig Production Farm
  • 8.3. Veterinary Clinics/Hospitals

9. Americas Porcine Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Porcine Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Porcine Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Zoetis Launches Circomax In The UK
    • 12.3.2. Merck Animal Health Launches 3-In-One Swine Vaccine
    • 12.3.3. Elanco is Exclusive U.S. Distributor of Aptimmune's PRRS Killed Autogenous Vaccine

Companies Mentioned

  • 1. Bayer AG
  • 2. Endovac Animal Health
  • 3. Merck & Co., Inc.
  • 4. FATRO S.p.A.
  • 5. Malaysian Vaccines & Pharmaceuticals Sdn Bhd.
  • 6. Yenher Agro-Products Sdn. Bhd.
  • 7. Boehringer Ingelheim International GmbH
  • 8. Biogenesis Bago S.A.
  • 9. Formosa Biomedical Inc.
  • 10. Indian Immunologicals Ltd.
  • 11. Kyoto Biken Laboratories, Inc.
  • 12. PBS Animal Health
  • 13. Bimeda Holdings PLC
  • 14. HIPRA, S.A.
  • 15. Zoetis Inc.
  • 16. Aptimmune Biologics, Inc.
  • 17. AVAC Vietnam Joint Stock Company
  • 18. Eli Lilly and Company
  • 19. Phibro Animal Health Corporation
  • 20. Arko Laboratories
  • 21. Genvax Technologies, Inc.
  • 22. Nisseiken Co., Ltd.
  • 23. Medgene Labs
  • 24. Virbac SA
  • 25. Ceva Sante Animale
  • 26. KM Biologics Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦